April 23rd 2024
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Introduction and CIRCULATE-Japan Overview
May 5th 2022Stacey A. Cohen, MD, and Mark Lewis, MD, introduce the 2022 ASCO GI abstract, “Association of Circulating Tumor DNA Dynamics With Clinical Outcomes in the Adjuvant Setting for Patients With Colorectal Cancer From an Observational GALAXY Study in CIRCULATE-Japan.”
Rachel Pearlman, MS, LGC, Discusses Fine Tuning Genetic/Germline Testing for CRC
March 30th 2022In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.
CYAD-101 CRC Trial Receives Clinical Hold Following Discussion With FDA
March 4th 2022A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.
Locoregional Liver-Directed Therapies to Treat Unresectable Colorectal Liver Metastases: A Review
This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.
This case presents a patient with locally advanced, unresectable, mismatch repair–deficient sigmoid colon cancer who was treated with neoadjuvant chemoimmunotherapy followed by surgical resection leading to a complete pathologic response after preoperative systemic chemoimmunotherapy.
Trend Identified Favoring First-Line Trifluridine/Tipiracil Plus Bevacizumab in Metastatic CRC
February 10th 2022Treatment with trifluridine/tipiracil plus bevacizumab trended towards favorability despite not demonstrating statistically significant superiority in patients with metastatic colorectal cancer.
Regorafenib Plus Pembrolizumab Combo Misses PFS End Point, Shows Strong OS for MSS Colorectal Cancer
January 22nd 2022Although the combination of regorafenib and pembrolizumab failed to meet significance for progression-free survival, an improvement in overall survival and disease control were observed for patients with microsatellite stable colorectal cancer.
Higher 60-Day Mortality Seen After Primary Tumor Resection Followed by Systemic Treatment in mCRC
December 23rd 2021Phase 3 data indicated that primary tumor resection followed by systemic treatment produced higher 60-day mortality vs systemic treatment alone for patients with metastatic colorectal cancer.